Q2 Solutions Q2 Solutions Actionable Insights for Better Health and Lab Solutions
Blog
Victor Weigman, Ph.D. | February 03, 2016

Precision medicine: Shifting from one drug for all patients to personalized genomics-based therapeutic options by Victor Weigman

Victor Weigman, Ph.D., Associate Director, Translational Genomics, Q2 Solutions, a Quintiles Quest Joint Venture
Patrice Hugo, Ph.D., Chief Scientific Officer, Q2 Solutions, a Quintiles Quest Joint Venture

With advancements in clinical informatics and genomics, there has been a paradigm shift from “one drug fits all” toward precision medicine – taking account of individual variability in genes, environment and lifestyle – across therapeutic areas. Precision medicine allows identification of patients who would likely benefit the most from a treatment and suffer the least side effects. For instance, such screening can reveal genetic makeup likely aligned with the molecular mechanisms of action of a drug, increasing the probability of a patient’s response to the therapy. This helps find better matches for existing and novel drugs, with the goal of ensuring that the right drug is used in the right patient at the right time.

To read more, access this whitepaper. 

Related Services: